Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments - Additional Information (Detail)

v3.23.2
Financial Instruments - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 14, 2021
Sep. 30, 2022
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Nov. 16, 2021
Schedule Of Available For Sale Securities [Line Items]            
Contingent consideration, current         $ 8,067,000  
Sale of stock price per share           $ 27.74
Impairment     $ 0 $ 0    
Other Assets | Level 2            
Schedule Of Available For Sale Securities [Line Items]            
Strategic investment     2,750,000 2,750,000 $ 2,750,000  
Investment at fair value     $ 2,021,000 $ 2,021,000    
Pandologic Ltd [Member]            
Schedule Of Available For Sale Securities [Line Items]            
Business acquisition, effective date of acquisition Sep. 14, 2021          
Business acquisition, percentage of ownership interests acquired 100.00%          
Business acquisition, name of acquired entity PandoLogic, Ltd. (“PandoLogic”)          
Business acquisition, date of acquisition agreement Jul. 21, 2021          
Stock Consideration [Member] | PandoLogic Merger Agreement [Member]            
Schedule Of Available For Sale Securities [Line Items]            
Sale of stock price per share     $ 20.53 $ 20.53    
Minimum [Member]            
Schedule Of Available For Sale Securities [Line Items]            
Contingent earnout   $ 10,825,000        
Maximum [Member] | Pandologic Ltd [Member]            
Schedule Of Available For Sale Securities [Line Items]            
Contingent consideration, current $ 65,000,000